Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin + acarbose versus metformin + sitagliptin for postprandial glucose management in type 2 diabetes
ChiCTR2000039424Phase 4Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Nov 2020
- Modality
- Small Molecules, Microbiome-Derived Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of metformin, acarbose and sitagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: Flash continuous glucose monitoring data. Started Nov 2020; status: recruiting.
02
Drugs
metforminacarbosesitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2000039424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039424.